EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 810 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... July 23, 2020 How Do Black People with Cancer View Clinical Research? November 15, 2024 Digital Breast Tomosynthesis Found to Detect Invasive Cancers At a Higher... December 8, 2020 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Load more HOT NEWS Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... EMA Recommends Granting a Marketing Authorisation for Nirogacestat Studying Molecular Subtypes of Peritoneal Metastases in Gastric Cancer NCI Launches New Resource for Specimens and Data from Cancer Clinical...
